DiagnaMed Secures Trademark For BRAIN AGE Brand In Canada
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) has been granted a trademark for its BRAIN AGE brand. The trademark approval, which comes from the Canadian Intellectual Property Office, was announced this morning by the company.
The trademark is good for the commercial use throughout Canada for the use of BRAIN AGE as a neurological monitoring apparatus, brain monitoring apparatus, and electroencephalogram-based apparatus. The BRAIN AGE estimation solution is part of DiagnaMed’s CERVAI Brain Health AI Platform, which as the name suggests estimates brain age and generates a brain health score.
The tech behind the CERVAI platform is based on research and development conducted by Drexel University and the University of Miami, which has been developed as means of screening for potential brain health issues. The platform uses an EEG headset to collect neural activity data, which is then incorporated with a proprietary machine-learning model.
A commercial pilot program is currently underway in Canada and the United States at several clinics, which is open to a select 25 clinics that are focused on health and wellness, sports and physical therapy, mental health, or clinical research for neurological and cognitive disorders.
READ: DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada
The acquisition of a trademark for BRAIN AGE follows DiagnaMed focusing on strengthening its intellectual property under the Intellectual Property Ontario Partner Program and the National Research Council of Canada Industrial Research Assistance Program IP Assist Program. DiagnaMed sought IP protection following significant progress that was made in the development of its AI algorithms and software, and the achievement of certain milestones in its research.
DiagnaMed Holdings last traded at $0.065 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
